EBV-positive human sera contain antibodies against the EBV BMRF-2 protein

Virology

Volumn 393, Issue 1, 2009, Pages 151-159

  Xiao, Jianqiao ^a   Palefsky, Joel M ^a,b   Herrera, Rossana ^a   Sunshine, Carl ^a   Tugizov, Sharof M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antigenicity; BMRF 2; Epstein Barr virus; Humoral immune response; Immunodominant epitope; Protein

Indexed keywords

ARGININE; ASPARAGINE; GLYCINE; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; PROTEIN BMRF 2; PROTEIN BMRF 2 ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; MOUTH MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN DOMAIN; PROTEIN MOTIF; SERUM; VIRUS INFECTION; VIRUS REACTIVATION;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; EPITHELIAL CELLS; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; MEMBRANE GLYCOPROTEINS; NEUTRALIZATION TESTS; VIRAL PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 70349316245     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.07.025     Document Type: Article

References (58)

1. Alconada A., Bauer U., Baudoux L., Piette J., and Hoflack B. Intracellular transport of the glycoproteins gE and gI of the varicella-zoster virus. gE accelerates the maturation of gI and determines its accumulation in the trans-Golgi network. J. Biol. Chem. 273 22 (1998) 13430-13436
2. Balan P., Davis P.N., Bell S., Atkinson H., Browne H., and Minson T. An analysis of the in vitro and in vivo phenotypes of mutants of herpes simplex virus type 1 lacking glycoproteins gG, gE, gI or the putative gJ. J. Gen. Virol. 75 Pt. 6 (1994) 1245-1258
3. Beisel C., Tanner J., Matsuo T., Thorley-Lawson D., Kezdy F., and Kieff E. Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene. J. Virol. 54 (1985) 665-674
4. Brack A.R., Klupp B.G., Granzow H., Tirabassi R., Enquist L.W., and Mettenleiter T.C. Role of the cytoplasmic tail of pseudorabies virus glycoprotein E in virion formation. J. Virol. 74 9 (2000) 4004-4016
5. Chapman A.L., Rickinson A.B., Thomas W.A., Jarrett R.F., Crocker J., and Lee S.P. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res. 61 16 (2001) 6219-6226
6. Corey L., and Spear P.G. Infections with herpes simplex viruses (1). N. Engl. J. Med. 314 11 (1986) 686-691
7. Coulter L.J., and Reid H.W. Isolation and expression of three open reading frames from ovine herpesvirus-2. J. Gen. Virol. 83 Pt. 3 (2002) 533-543
8. de Jong A., Palefsky J.M., Stites D.P., and Nakagawa M. Human immunodeficiency virus-positive individuals with oral hairy leukoplakia are able to mount cytotoxic T lymphocyte responses to Epstein-Barr virus. Oral Dis. 6 1 (2000) 40-47
9. Dingwell K.S., and Johnson D.C. The herpes simplex virus gE-gI complex facilitates cell-to-cell spread and binds to components of cell junctions. J. Virol. 72 11 (1998) 8933-8942
10. Dingwell K.S., Brunetti C.R., Hendricks R.L., Tang Q., Tang M., Rainbow A.J., and Johnson D.C. Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells. J. Virol. 68 2 (1994) 834-845
11. Epstein M.A., and Morgan A.J. Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine. Clin. Exp. Immunol. 53 2 (1983) 257-271
12. Farnsworth A., and Johnson D.C. Herpes simplex virus gE/gI must accumulate in the trans-Golgi network at early times and then redistribute to cell junctions to promote cell-cell spread. J. Virol. 80 7 (2006) 3167-3179
13. Finerty S., Tarlton J., Mackett M., Conway M., Arrand J.R., Watkins P.E., and Morgan A.J. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. J. Gen. Virol. 73 Pt. 2 (1992) 449-453
14. Finerty S., Mackett M., Arrand J.R., Watkins P.E., Tarlton J., and Morgan A.J. Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum. Vaccine 12 13 (1994) 1180-1184
15. Gill M.B., Edgar R., May J.S., and Stevenson P.G. A gamma-herpesvirus glycoprotein complex manipulates actin to promote viral spread. PLoS ONE 3 3 (2008) e1808
16. Gore M., and Hutt-Fletcher L.M. The BDLF2 protein of Epstein-Barr virus is a type II glycosylated envelope protein whose processing is dependent on coexpression with the BMRF2 protein. Virology (2008)
17. Greenspan D., and Greenspan J.S. Oral manifestations of HIV infection. AIDS Clin. Care 9 4 (1997) 29-33
18. Greenspan J.S., Greenspan D., Lennette E.T., Abrams D.I., Conant M.A., Petersen V., and Freese U.K. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N. Engl. J. Med. 313 25 (1985) 1564-1571
19. Greenspan D., Greenspan J.S., Hearst N.G., Pan L.Z., Conant M.A., Abrams D.I., Hollander H., and Levy J.A. Relation of oral hairy leukoplakia to infection with the human immunodeficiency virus and the risk of developing AIDS. J. Infect. Dis. 155 3 (1987) 475-481
20. Gu S.Y., Huang T.M., Ruan L., Miao Y.H., Lu H., Chu C.M., Motz M., and Wolf H. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev. Biol. Stand. 84 (1995) 171-177
21. Hayes D.P., Brink A.A., Vervoort M.B., Middeldorp J.M., Meijer C.J., and van den Brule A.J. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. Mol. Pathol. 52 2 (1999) 97-103
22. Henle W., Henle G., Niederman J.C., Klemola E., and Haltia K. Antibodies to early antigens induced by Epstein-Barr virus in infectious mononucleosis. J. Infect. Dis. 124 1 (1971) 58-67
23. Hosein B., Fang C.T., Popovsky M.A., Ye J., Zhang M., and Wang C.Y. Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein. Proc. Natl. Acad. Sci. U.S.A. 88 9 (1991) 3647-3651
24. Johannsen E., Luftig M., Chase M.R., Weicksel S., Cahir-McFarland E., Illanes D., Sarracino D., and Kieff E. Proteins of purified Epstein-Barr virus. Proc. Natl. Acad. Sci. U.S.A. 101 46 (2004) 16286-16291
25. Johnson D.C., and Huber M.T. Directed egress of animal viruses promotes cell-to-cell spread. J. Virol. 76 1 (2002) 1-8
26. Johnson D.C., Webb M., Wisner T.W., and Brunetti C. Herpes simplex virus gE/gI sorts nascent virions to epithelial cell junctions, promoting virus spread. J. Virol. 75 2 (2001) 821-833
27. Joki-Korpela P., Roivainen M., Lankinen H., Poyry T., and Hyypia T. Antigenic properties of human parechovirus 1. J. Gen. Virol. 81 Pt. 7 (2000) 1709-1718
28. Khanna R., Burrows S.R., and Moss D.J. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59 3 (1995) 387-405
29. Liebermann H., Dolling R., Schmidt D., and Thalmann G. RGD-containing peptides of VP1 of foot-and-mouth disease virus (FMDV) prevent virus infection in vitro. Acta Virol. 35 1 (1991) 90-93
30. Loesing J.B., Di Fiore S., Ritter K., Fischer R., and Kleines M. The BDLF2/BMRF2 complex of EBV affects the cellular morphology. J. Gen. Virol. (2009)
31. Mason P.W., Rieder E., and Baxt B. RGD sequence of foot-and-mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement pathway. Proc. Natl. Acad. Sci. U.S.A. 91 5 (1994) 1932-1936
32. May J.S., de Lima B.D., Colaco S., and Stevenson P.G. Intercellular gamma-herpesvirus dissemination involves co-ordinated intracellular membrane protein transport. Traffic 6 9 (2005) 780-793
33. May J.S., Walker J., Colaco S., and Stevenson P.G. The murine gammaherpesvirus 68 ORF27 gene product contributes to intercellular viral spread. J. Virol. 79 8 (2005) 5059-5068
34. McAulay K.A., Haque T., Urquhart G., Bellamy C., Guiretti D., and Crawford D.H. Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease. J. Immunol. 182 6 (2009) 3892-3901
35. McMillan T.N., and Johnson D.C. Cytoplasmic domain of herpes simplex virus gE causes accumulation in the trans-Golgi network, a site of virus envelopment and sorting of virions to cell junctions. J. Virol. 75 4 (2001) 1928-1940
36. Morgan A.J. Epstein-Barr virus vaccines. Vaccine 10 9 (1992) 563-571
37. Moss D.J., Burrows S.R., Khanna R., Misko I.S., and Sculley T.B. Immune surveillance against Epstein-Barr virus. Semin. Immunol. 4 2 (1992) 97-104
38. Moutschen M., Leonard P., Sokal E.M., Smets F., Haumont M., Mazzu P., Bollen A., Denamur F., Peeters P., Dubin G., and Denis M. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25 24 (2007) 4697-4705
39. Palefsky J.M., Peñaranda M.E., Pierik L.T., Lagenaur L.A., MacPhail L.A., Greenspan D., and Greenspan J.S. Epstein-Barr virus BMRF-2 and BDLF-3 expression in hairy leukoplakia. Oral Dis. 3 Suppl. 1(8) (1997) S171-S176
40. Pearson G.R., Weiland L.H., Neel III H.B., Taylor W., Earle J., Mulroney S.E., Goepfert H., Lanier A., Talvot M.L., Pilch B., Goodman M., Huang A., Levine P.H., Hyams V., Moran E., Henle G., and Henle W. Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. Cancer 51 2 (1983) 260-268
41. Peñaranda M.E., Lagenaur L.A., Pierik L.T., Berline J.W., MacPhail L.A., Greenspan D., Greenspan J.S., and Palefsky J.M. Expression of Epstein-Barr virus BMRF-2 and BDLF-3 genes in hairy leukoplakia [published erratum appears in J. Gen. Virol. 1998. May;79(Pt. 5):1321]. J. Gen. Virol. 78 Pt. 12)(8 (1997) 3361-3370
42. Polcicova K., Goldsmith K., Rainish B.L., Wisner T.W., and Johnson D.C. The extracellular domain of herpes simplex virus gE is indispensable for efficient cell-to-cell spread: evidence for gE/gI receptors. J. Virol. 79 18 (2005) 11990-12001
43. Rickinson A.B., and Moss D.J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15 (1997) 405-431
44. Rickinson A., and Kieff E. Epstein-Barr virus. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields Virology 2 (2007), Lippincott-Williams and Wilkins, Philadelphia
45. Ringborg U., Henle W., Henle G., Ingimarsson S., Klein G., Silfversward C., and Strander H. Epstein-Barr virus-specific serodiagnostic tests in carcinomas of the head and neck. Cancer 52 7 (1983) 1237-1243
46. Rowe M., Finke J., Szigeti R., and Klein G. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J. Gen. Virol. 69 Pt. 6 (1988) 1217-1228
47. Sashihara J., Burbelo P.D., Savoldo B., Pierson T.C., and Cohen J.I. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology (2009)
48. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat. Rev., Microbiol. 6 11 (2008) 815-826
49. Savoldo B., Goss J., Liu Z., Huls M.H., Doster S., Gee A.P., Brenner M.K., Heslop H.E., and Rooney C.M. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 72 6 (2001) 1078-1086
50. Savoldo B., Rooney C.M., Di Stasi A., Abken H., Hombach A., Foster A.E., Zhang L., Heslop H.E., Brenner M.K., and Dotti G. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 110 7 (2007) 2620-2630
51. Shimakage M., Kawahara K., Sasagawa T., Inoue H., Yutsudo M., Yoshida A., and Yanoma S. Expression of Epstein-Barr virus in thyroid carcinoma correlates with tumor progression. Hum. Pathol. 34 11 (2003) 1170-1177
52. Sokal E.M., Hoppenbrouwers K., Vandermeulen C., Moutschen M., Leonard P., Moreels A., Haumont M., Bollen A., Smets F., and Denis M. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 196 12 (2007) 1749-1753
53. Thorley-Lawson D.A., and Geilinger K. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc. Natl. Acad. Sci. U.S.A. 77 9 (1980) 5307-5311
54. Tugizov S.M., Berline J.W., and Palefsky J.M. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat. Med. 9 3 (2003) 307-314
55. Wang C.Y. Synthetic-peptide-based immunodiagnosis of retrovirus infections: current status and future prospects. Adv. Biotechnol. Process. 10 (1988) 131-148
56. Xiao J., Palefsky J.M., Herrera R., and Tugizov S.M. Characterization of the Epstein-Barr virus glycoprotein BMRF-2. Virology 359 2 (2007) 382-396
57. Xiao J., Palefsky J.M., Herrera R., Berline J., and Tugizov S.M. The Epstein-Barr virus BMRF-2 protein facilitates virus attachment to oral epithelial cells. Virology 370 2 (2008) 430-442
58. Xiao J., Palefsky J.M., Herrera R., Berline J., and Tugizov S.M. EBV BMRF-2 facilitates cell-to-cell spread of virus within polarized oral epithelial cells. Virology 388 2 (2009) 335-343